Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

被引:328
作者
Ford, Alexander C. [1 ]
Talley, Nicholas J. [2 ]
Spiegel, Brennan M. R. [3 ,4 ]
Foxx-Orenstein, Amy E. [5 ]
Schiller, Lawrence [6 ]
Quigley, Eamonn M. M. [7 ]
Moayyedi, Paul [1 ]
机构
[1] McMaster Univ, Hlth Sci Ctr, Div Gastroenterol, Hamilton, ON L8N 3Z5, Canada
[2] Mayo Clin, Dept Med, Jacksonville, FL 32224 USA
[3] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA USA
[4] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[5] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
[6] Baylor Univ, Med Ctr, Digest Hlth Assoc Texas, Dallas, TX USA
[7] Cork Univ Hosp, Dept Med, Cork, Ireland
来源
BMJ-BRITISH MEDICAL JOURNAL | 2008年 / 337卷
关键词
D O I
10.1136/bmj.a2313
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine the effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome. Design Systematic review and meta- analysis of randomised controlled trials. Data sources Medline, Embase, and the Cochrane controlled trials register up to April 2008. Review methods Randomised controlled trials comparing fibre, antispasmodics, and peppermint oil with placebo or no treatment in adults with irritable bowel syndrome were eligible for inclusion. The minimum duration of therapy considered was one week, and studies had to report either a global assessment of cure or improvement in symptoms, or cure of or improvement in abdominal pain, after treatment. A random effects model was used to pool data on symptoms, and the effect of therapy compared with placebo or no treatment was reported as the relative risk (95% confidence interval) of symptoms persisting. Results 12 studies compared fibre with placebo or no treatment in 591 patients (relative risk of persistent symptoms 0.87, 95% confidence interval 0.76 to 1.00). This effect was limited to ispaghula (0.78, 0.63 to 0.96). Twenty two trials compared antispasmodics with placebo in 1778 patients (0.68, 0.57 to 0.81). Various antispasmodics were studied, but otilonium (four trials, 435 patients, relative risk of persistent symptoms 0.55, 0.31 to 0.97) and hyoscine (three trials, 426 patients, 0.63, 0.51 to 0.78) showed consistent evidence of efficacy. Four trials compared peppermint oil with placebo in 392 patients ( 0.43, 0.32 to 0.59). Conclusion Fibre, antispasmodics, and peppermint oil were all more effective than placebo in the treatment of irritable bowel syndrome.
引用
收藏
页码:1388 / 1392
页数:11
相关论文
共 32 条
  • [11] HARVEY RF, 1973, LANCET, V1, P1278
  • [12] Measuring inconsistency in meta-analyses
    Higgins, JPT
    Thompson, SG
    Deeks, JJ
    Altman, DG
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414): : 557 - 560
  • [13] Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population
    Hillilä, MT
    Färkkilä, MA
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (03) : 339 - 345
  • [14] THE MECHANISM OF ACTION OF PEPPERMINT OIL ON GASTROINTESTINAL SMOOTH-MUSCLE - AN ANALYSIS USING PATCH CLAMP ELECTROPHYSIOLOGY AND ISOLATED TISSUE PHARMACOLOGY IN RABBIT AND GUINEA-PIG
    HILLS, JM
    AARONSON, PI
    [J]. GASTROENTEROLOGY, 1991, 101 (01) : 55 - 65
  • [15] The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects
    Hungin, APS
    Whorwell, PJ
    Tack, J
    Mearin, F
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (05) : 643 - 650
  • [16] Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
    Jadad, AR
    Moore, RA
    Carroll, D
    Jenkinson, C
    Reynolds, DJM
    Gavaghan, DJ
    McQuay, HJ
    [J]. CONTROLLED CLINICAL TRIALS, 1996, 17 (01): : 1 - 12
  • [17] Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials
    Jailwala, J
    Imperiale, TF
    Kroenke, K
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (02) : 136 - 147
  • [18] Systematic reviews in health care -: Assessing the quality of controlled clinical trials
    Jüni, P
    Altman, DG
    Egger, M
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2001, 323 (7303): : 42 - 46
  • [19] Meta-analysis: the treatment of irritable bowel syndrome
    Lesbros-Pantoflickova, D
    Michetti, P
    Fried, M
    Beglinger, C
    Blum, AL
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (11-12) : 1253 - 1269
  • [20] Functional bowel disorders
    Longstreth, George F.
    Thompson, W. Grant
    Chey, William D.
    Houghton, Lesley A.
    Mearin, Fermin
    Spiller, Robin C.
    [J]. GASTROENTEROLOGY, 2006, 130 (05) : 1480 - 1491